Patents by Inventor Stephen DEWEY

Stephen DEWEY has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD OF TREATING TOURETTE'S DISORDER WITH GABA-AMINOTRANSFERASE INACTIVATORS
    Publication number: 20160151316
    Abstract: The present invention is a method of treating Tourette's Disorder (TD) using GABA ergic drugs that elevate the amount of stored presynaptic GABA and do not significantly increase GABA tone (a continuous background level of GABA signaling) in the brain. The administration of vigabatrin and/or (1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid hydrochloride salt is expressly contemplated.
    Type: Application
    Filed: February 8, 2016
    Publication date: June 2, 2016
    Inventors: Steven MILLER, Jonathan D. BRODIE, Stephen DEWEY
  • Method of treating Tourette'S disorder with GABA-aminotransferase inactivators
    Patent number: 9254274
    Abstract: The present invention is a method of treating Tourette's Disorder (TD) using GABA ergic drugs that elevate the amount of stored presynaptic GABA and do not significantly increase GABA tone (a continuous background level of GABA signaling) in the brain. The administration of vigabatrin and/or (1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid hydrochloride salt is expressly contemplated.
    Type: Grant
    Filed: July 25, 2014
    Date of Patent: February 9, 2016
    Assignees: Catalyst Pharmaceutical Partners, Inc., New York University, Feinstein Institute for Medical Research
    Inventors: Steven Miller, Jonathan D. Brodie, Stephen Dewey
  • METHOD OF TREATING TOURETTE'S DISORDER WITH GABA-AMINOTRANSFERASE INACTIVATORS
    Publication number: 20140336256
    Abstract: The present invention is a method of treating Tourette's Disorder (TD) using GABA ergic drugs that elevate the amount of stored presynaptic GABA and do not significantly increase GABA tone (a continuous background level of GABA signaling) in the brain. The administration of vigabatrin and/or (1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid hydrochloride salt is expressly contemplated.
    Type: Application
    Filed: July 25, 2014
    Publication date: November 13, 2014
    Inventors: Steven MILLER, Jonathan D. BRODIE, Stephen DEWEY